Sampre Nutritions Ltd is Rated Sell

Current Rating and Its Significance

MarketsMOJO currently assigns Sampre Nutritions Ltd a 'Sell' rating, indicating a cautious stance for investors. This rating suggests that the stock may underperform relative to the broader market or sector peers in the near to medium term. It is important to understand that this recommendation is based on a comprehensive evaluation of multiple parameters, including quality, valuation, financial trends, and technical indicators, all assessed with the latest available data as of 28 February 2026.

Quality Assessment: Below Average Fundamentals

As of 28 February 2026, Sampre Nutritions Ltd exhibits below average quality metrics. The company’s long-term fundamental strength remains weak, with a concerning compound annual growth rate (CAGR) of operating profits at -217.19% over the past five years. This steep decline highlights significant challenges in sustaining profitability and operational efficiency. Additionally, the average Return on Equity (ROE) stands at a modest 2.77%, signalling limited profitability generated per unit of shareholders’ funds. Such figures suggest that the company struggles to deliver consistent value to its investors through core business operations.

Valuation: Risky Investment Profile

The valuation grade for Sampre Nutritions Ltd is classified as risky. Despite the stock’s impressive one-year return of 144.66% as of 28 February 2026, this performance contrasts sharply with the company’s deteriorating profit margins, which have fallen by 526% over the same period. The stock currently trades at valuations that are elevated relative to its historical averages, raising concerns about sustainability and potential overvaluation. Moreover, the company’s negative EBITDA further compounds the risk profile, indicating operational losses before accounting for interest, taxes, depreciation, and amortisation.

Financial Trend: Mixed Signals Amid Debt Concerns

Financially, Sampre Nutritions Ltd presents a mixed picture. While the financial grade is positive, reflecting some recent improvements or stabilisation, the company faces significant debt servicing challenges. The Debt to EBITDA ratio is notably high at 5.03 times, implying that earnings before interest, taxes, depreciation, and amortisation are insufficient to comfortably cover debt obligations. This elevated leverage heightens financial risk, especially in volatile market conditions. Investors should be mindful that such debt levels can constrain future growth and increase vulnerability to economic downturns.

Technical Outlook: Mildly Bullish Momentum

From a technical perspective, the stock shows mildly bullish signals. Recent price movements include a 1-day gain of 1.53% and a 1-week increase of 7.92%, although the 3-month trend is negative at -35.47%. The 6-month return is positive at 16.25%, but the year-to-date performance remains subdued at -11.82%. These mixed technical indicators suggest some short-term buying interest, but the overall trend remains uncertain. Investors relying on technical analysis should weigh these signals carefully alongside fundamental concerns.

Here's How Sampre Nutritions Ltd Looks Today

As of 28 February 2026, the stock’s microcap status within the FMCG sector means it is subject to higher volatility and liquidity constraints compared to larger peers. The current Mojo Score of 39.0, up from 29.0 on 19 August 2025, reflects a modest improvement in the company’s outlook but remains within the 'Sell' grade category. This score encapsulates the combined assessment of quality, valuation, financial health, and technical factors, providing a holistic view for investors.

Investors should note that while the stock has delivered strong returns over the past year, these gains are not supported by robust earnings growth or operational improvements. The negative EBITDA and high debt levels pose significant risks, and the below average quality metrics suggest that the company may face ongoing challenges in generating sustainable shareholder value.

Investor Implications and Considerations

For investors, the 'Sell' rating on Sampre Nutritions Ltd serves as a cautionary signal. It suggests that the stock may not be an attractive buy at current levels due to fundamental weaknesses and valuation risks. Those holding the stock should carefully monitor the company’s financial health, particularly its ability to manage debt and improve profitability. Prospective investors might consider waiting for clearer signs of operational turnaround or more favourable valuation before committing capital.

It is also essential to consider the broader FMCG sector dynamics and market conditions, as these can influence the company’s prospects. While the technical indicators show some short-term bullishness, the underlying financial and quality metrics warrant a conservative approach.

Summary

In summary, Sampre Nutritions Ltd’s current 'Sell' rating by MarketsMOJO, last updated on 19 August 2025, reflects a comprehensive evaluation of its below average quality, risky valuation, mixed financial trends, and mildly bullish technical outlook. As of 28 February 2026, the stock’s strong recent returns are overshadowed by significant operational and financial challenges, advising investors to exercise caution and prioritise risk management in their portfolio decisions.

About MarketsMOJO Ratings

MarketsMOJO’s rating system integrates multiple dimensions of stock analysis to provide investors with actionable insights. The 'Sell' rating indicates that the stock is expected to underperform relative to the market or sector benchmarks, based on current data and trends. This rating helps investors align their strategies with prevailing market realities and company fundamentals.

Final Thoughts

While Sampre Nutritions Ltd’s stock price has shown volatility and some positive momentum, the fundamental and financial indicators suggest that the company faces considerable headwinds. Investors should weigh these factors carefully and consider their risk tolerance before making investment decisions related to this stock.

Only Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Start Today